ライフサイエンスコーパス: AIDS vaccine

1 nAbs) may be invaluable for the design of an AIDS vaccine.

2 iretroviral therapy or efforts to develop an AIDS vaccine.

3 ssist in establishing goals for an effective AIDS vaccine.

4 adjuvant for the development of a nasal HIV/AIDS vaccine.

5 uvant is a crucial step toward a mucosal HIV/AIDS vaccine.

6 guidance for the development of a potential AIDS vaccine.

7 ity could provide the basis for an effective AIDS vaccine.

8 e hurdles in the development of an effective AIDS vaccine.

9 vergent strains is a desirable feature of an AIDS vaccine.

10 e a CTL response, a desirable feature for an AIDS vaccine.

11 for the development of a safe and effective AIDS vaccine.

12 to serve as both a prime and a boost for an AIDS vaccine.

13 an important characteristic of a successful AIDS vaccine.

14 d immunity may be essential for an effective AIDS vaccine.

15 ely to be a critical feature of an effective AIDS vaccine.

16 d to the formulation of a safe and effective AIDS vaccine.

17 eclinical evaluation of 1F7 as a therapeutic AIDS vaccine.

18 g pursued in attempts to create an effective AIDS vaccine.

19 confronting the development of a successful AIDS vaccine.

20 ccines for development of an efficacious HIV/AIDS vaccine.

21 ited for the development of an effective HIV/AIDS vaccine.

22 nes represent a promising approach to an HIV/AIDS vaccine.

23 is a major goal toward the development of an AIDS vaccine.

24 gnificantly contribute to an efficacious HIV/AIDS vaccine.

25 m complicates the design of an effective HIV/AIDS vaccine.

26 development of a safe and highly immunogenic AIDS vaccine.

27 otentially desirable feature of a preventive AIDS vaccine.

28 2-like neutralizing Abs and contribute to an AIDS vaccine.

29 h-avidity mucosal CTL induced by the mucosal AIDS vaccine.

30 s and serves as a tool to evaluate candidate AIDS vaccines.

31 ropism, and increasing the immunogenicity of AIDS vaccines.

32 1 have become popular targets for candidate AIDS vaccines.

33 as the baseline intervention for future HIV/AIDS vaccines.

34 This fusion protein may be useful for AIDS vaccines.

35 prognostic indicators to evaluate candidate AIDS vaccines.

36 represent a promising platform for candidate AIDS vaccines.

37 fic antibody responses elicited by candidate AIDS vaccines.

38 considered in the development and testing of AIDS vaccines.

39 iversification process limit the efficacy of AIDS vaccines.

40 ed epitopes could be important components of AIDS vaccines.

41 in immunogen design and testing of candidate AIDS vaccines.

42 properly assessing the efficacy of candidate AIDS vaccines.

43 ich serves as the primary proving ground for AIDS vaccines.

44 e the immune correlates of protection for an AIDS vaccine?

45 mucosal immunity important for an effective AIDS vaccine?

46 that underpin the rational development of an AIDS vaccine: (1) Will natural infection with HIV protec

47 A satellite symposium at the AIDS Vaccine 2012 conference brought together many of th

48 bjects in phase I and II trials of candidate AIDS vaccines, 23 were diagnosed with intercurrent human

49 odeficiency viruses that may advance the HIV/AIDS vaccine agenda.

50 it an attractive candidate vector for a HIV/AIDS vaccine aimed at eliciting cell-mediated immune res

51 d be important for developing and evaluating AIDS vaccines, although DNA sequencing remains necessary

52 ey site of virus replication, with a mucosal AIDS vaccine ameliorates infection by SHIV in non-human

53 reasingly used in the screening of candidate AIDS vaccine and immunization strategies for advancement

54 he development of the next generation of HIV/AIDS vaccines and immune-based therapies.

55 A combination AIDS vaccine approach consisting of priming with adenovi

56 Here, we show that a prime/boost AIDS vaccine approach elicits potent ADCC activity corre

57 elevance to the design of an efficacious HIV/AIDS vaccine are also highlighted.

58 HIV/AIDS vaccines are crucial for controlling the HIV epidem

59 evelopment of a novel strategy for a mucosal AIDS vaccine, as well as vaccines to combat other oral d

60 We developed an AIDS vaccine based on attenuated VSV vectors expressing

61 ply deleted SIV is pathogenic and that human AIDS vaccines built on similar prototypes may cause AIDS

62 tribute to the design of population-targeted AIDS vaccines by effectively capturing the diversity of

63 V144 trial demonstrated that an experimental AIDS vaccine can prevent human immunodeficiency virus ty

64 Human adenovirus (AdHu)-based candidate AIDS vaccine can provide protection from simian immunode

65 hese data demonstrate that certain candidate AIDS vaccines can elicit antibodies that neutralize a pr

66 NYVAC vector could be a novel optimized HIV/AIDS vaccine candidate for human clinical trials.

67 ese poxvirus vectors could be considered HIV/AIDS vaccine candidates based on their activation of pot

68 d novel replicating poxvirus NYVAC-based HIV/AIDS vaccine candidates expressing clade C HIV-1 antigen

69 n, one of the major models for evaluation of AIDS vaccine candidates.

70 d and will influence the design of candidate AIDS vaccines capable of eliciting effective neutralizin

71 In efforts to develop AIDS vaccine components, we generated combinatorial libr

72 g a critical advance in developing effective AIDS vaccine components.

73 A recent clinical trial of a T-cell-based AIDS vaccine delivered with recombinant adenovirus type

74 AIDS vaccine design requires a scientifically driven, ra

75 enetic diversity of HIV-1C and facilitate an AIDS vaccine design, particularly if the assumption that

76 udies with potentially huge consequences for AIDS vaccine design.

77 m studies of pathogenesis and strategies for AIDS vaccine design.

78 e glycan shield of HIV with implications for AIDS vaccine design.

79 nsights that might be relevant for effective AIDS vaccine design.

80 critical neutralization targets for rational AIDS vaccine design.

81 t choice of epitopes might be critical in an AIDS vaccine designed to protect against disease in the

82 utralizing antibodies is a high priority for AIDS vaccine development but one that has proven difficu

83 occurring envelope glycoproteins as well as AIDS vaccine development efforts targeted against a broa

84 Here, we place HIV/AIDS vaccine development in the context of the basic imm

85 The utility of nonhuman primate models in AIDS vaccine development is strengthened by the availabi

86 A major goal of AIDS vaccine development is to design vaccination strate

87 ata from the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) 001 trial, the

88 n neonates and have general implications for AIDS vaccine development, as the epitopes recognized by

89 These data suggest a new paradigm for AIDS vaccine development--vaccines capable of generating

90 irus (HIV-1) represents a major obstacle for AIDS vaccine development.

91 and this diversity poses a major obstacle to AIDS vaccine development.

92 protection and provide a rational basis for AIDS vaccine development.

93 isolates has been a tremendous challenge for AIDS vaccine development.

94 tection, thus providing a rational basis for AIDS vaccine development.

95 caque is currently the best animal model for AIDS vaccine development.

96 onal viral components for immune therapy and AIDS vaccine development.

97 the use of the rabbit as an animal model in AIDS vaccine development.

98 ct the specificity of antibody responses for AIDS vaccine development.

99 g de novo infections, could be important for AIDS vaccine development.

100 model in studying antibody responses in HIV/AIDS vaccine development.

101 the progression of disease is important for AIDS vaccine development.

102 nsmission and discuss strategies for mucosal AIDS vaccine development.

103 st immune responses are major challenges for AIDS vaccine development.

104 With the discovery of HIV/AIDS, vaccine development has been confronted by an agen

105 The seven AIDS vaccine efficacy trials have yielded extremely disa

106 ringency is needed for government support of AIDS vaccine efficacy trials.

107 can aid design of new strategies to enhance AIDS vaccine efficacy.

108 ntribute substantially to an efficacious HIV/AIDS vaccine, even after breakthrough infection.

109 Many in the HIV/AIDS vaccine field believe that the ability to elicit br

110 The development of an effective AIDS vaccine has been challenging because of viral genet

111 The design of an effective AIDS vaccine has eluded the efforts of the scientific co

112 To date, T-cell-based AIDS vaccines have been evaluated with validated techniq

113 hocyte (CTL) responses elicited by candidate AIDS vaccines have recently been shown to control viral

114 ome this, researchers who are developing HIV/AIDS vaccines have turned to the elicitation of cellular

115 The finding of a safe and effective HIV/AIDS vaccine immunogen is one of the main research prior

116 ects, identified by the NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI) 001 and 008 clinical tea

117 enesis and for evaluation as an experimental AIDS vaccine in rhesus macaques.

118 Because of this association, many AIDS vaccines in development are designed to generate vi

119 cine efficacy should guide the evaluation of AIDS vaccines in humans.

120 nv is highly desirable to evaluate candidate AIDS vaccines in nonhuman primates.

121 e C infection and to evaluate envelope-based AIDS vaccines in nonhuman primates.

122 and PG16 were isolated from an International AIDS Vaccine Initiative (IAVI) Protocol G subject infect

123 tic pairing, we analyzed donor International AIDS Vaccine Initiative 84, the source of antibodies PGT

124 23, the Wellcome Trust and the International AIDS Vaccine Initiative convened international experts i

125 The International AIDS Vaccine Initiative has established a consortium to

126 Rwanda and South Africa (IAVI, International Aids Vaccine Initiative), we evaluated the safety and im

127 International AIDS Vaccine Initiative, National Institutes of Health,

128 International AIDS Vaccine Initiative, United States Agency for Intern

129 Development of an effective AIDS vaccine is a global priority.

130 The quest for a prophylactic AIDS vaccine is ongoing, but it is now clear that the su

131 A primary goal in the development of an AIDS vaccine is the elicitation of broadly neutralizing

132 ge for the development of a highly effective AIDS vaccine is the identification of mechanisms of prot

133 iment to the development of an effective HIV/AIDS vaccine is the inefficiency with which human immuno

134 The goal of an effective AIDS vaccine is to generate immunity that will prevent h

135 lenge for human immunodeficiency virus (HIV)/AIDS vaccines is the elicitation of anti-Env antibodies

136 cell-mediated responses induced by candidate AIDS vaccines may be critical in determining postvaccina

137 immunity, suggesting that new benchmarks for AIDS vaccines may be in order.

138 These data suggest suggest that candidate AIDS vaccines may not simply be either efficacious or ne

139 can contribute to immune protection in this AIDS vaccine model.

140 An effective AIDS vaccine must control highly diverse circulating str

141 HIV-1/AIDS vaccines must address the extreme diversity of HIV-

142 In an effort to develop a useful AIDS vaccine or vaccine component, we have generated a c

143 ntal endpoint for evaluating the efficacy of AIDS vaccines or therapies in nonhuman primates.

144 roblems that are applicable to all Env-based AIDS vaccines regardless of the mechanism of antibody-me

145 up of rhesus macaques (RMs) that received an AIDS vaccine regimen and were subsequently protected aga

146 The goal of an AIDS vaccine regimen designed to induce cellular immune

147 ted as a potential component of a preventive AIDS vaccine regimen.

148 A range of current candidate AIDS vaccine regimens are focused on generating protecti

149 erties that make it an attractive vector for AIDS vaccine regimens.

150 The development of an effective AIDS vaccine remains the most promising long-term strate

151 nderstanding of the mechanisms of preventive AIDS vaccines remains a priority, and nonhuman primate (

152 .S. National Institutes of Health (NIH), HIV/AIDS vaccine research efforts will need to be carefully

153 ion campaigns in Africa, and malaria and HIV/AIDS vaccine research.

154 potency is an important goal of current HIV/AIDS vaccine research.

155 An effective AIDS vaccine should elicit strong humoral and cellular i

156 e in containing HIV replication, a candidate AIDS vaccine should generate virus-specific CTL response

157 An effective T-cell-based AIDS vaccine should induce strong HIV-specific CD8(+) T

158 s replicates will provide insight into where AIDS vaccines should produce immunity to be the most eff

159 relevant for the development of T-cell-based AIDS vaccines since they indicate that broad epitope-spe

160 Whereas several recent AIDS vaccine strategies have protected rhesus macaques a

161 r gene expression in response to alternative AIDS vaccine strategies with subsequent viral challenge

162 pe from CTL may be a limitation of CTL-based AIDS vaccine strategies.

163 imian immunodeficiency viruses (dSIVs) as an AIDS vaccine strategy.

164 cific neutralizing antibodies in preclinical AIDS vaccine studies in nonhuman primates.

165 represents a valuable tool to test candidate AIDS vaccines targeting HIV-1 clade C Env.

166 importance to find a safe and effective HIV/AIDS vaccine that can induce strong and broad T cell and

167 in the field of AIDS research, an effective AIDS vaccine that can prevent infection remains elusive.

168 Moreover, an AIDS vaccine that confers protection against clinical di

169 In an effort to develop an AIDS vaccine that elicits high-frequency cytotoxic-T-lym

170 n may be a major limitation of the CTL-based AIDS vaccines that are likely to be administered to larg

171 of SIVmac251 as a challenge strain to screen AIDS vaccines that elicit neutralizing antibodies as a m

172 m the basis for the development of candidate AIDS vaccines that would prevent infection, suppress pro

173 Despite the pressing need for an AIDS vaccine, the determinants of protective immunity to

174 ANCE It is likely necessary for an effective AIDS vaccine to elicit CD8(+) T cells with the ability t

175 aths to continue the pursuit of an effective AIDS vaccine to stem the global epidemic.

176 e used to determine the ability of candidate AIDS vaccines to generate neutralizing antibodies for cl

177 vaccine regimen.IMPORTANCE A failed phase II AIDS vaccine trial led to the hypothesis that CD4(+) T-c

178 These results have implications for future AIDS vaccine trials and the design of next-generation ge

179 V vectors are promising candidates for human AIDS vaccine trials because they propagate to high titer

180 ling of whole blood as an analytical tool in AIDS vaccine trials, providing unique insights into in v

181 maintaining CTL responses to an experimental AIDS vaccine vector based on live recombinant vesicular

182 improve the immunogenicity of MVA-based HIV/AIDS vaccines via the targeted deletion of specific poxv

183 creasing evidence suggests that an effective AIDS vaccine will need to elicit both broadly reactive h

184 An effective AIDS vaccine will need to protect against globally diver

185 vaccine trial subjects receiving a DNA/rAd5 AIDS vaccine with or without prior immunity to Ad5 were

186 discovery has been applied to developing an AIDS vaccine, yet this goal remains elusive.